tiprankstipranks
Achilles Therapeutics: Promising Q1 2024 Results
Company Announcements

Achilles Therapeutics: Promising Q1 2024 Results

Achilles Therapeutics Plc (ACHL) has released an update.

Don't Miss Our Christmas Offers:

Achilles Therapeutics Plc announced strong financial results for Q1 2024, with a cash reserve of $112.3 million, extending their operational runway through 2025. The company reported interim Phase I/IIa data on T cell therapies for advanced cancers, noting improvements and anticipating further data in the latter half of 2024. Research and development expenses decreased, contributing to a smaller net loss compared to the previous year.

For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAchilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million
TheFlyAchilles Therapeutics sells technology assets to AstraZeneca for $12M
TipRanks Auto-Generated NewsdeskAchilles Therapeutics Regains Nasdaq Compliance, Boosting Investor Confidence
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App